Literature DB >> 2993510

Interaction of opiates with opioid binding sites in the bovine adrenal medulla: II. Interaction with kappa sites.

E Castanas, N Bourhim, P Giraud, F Boudouresque, P Cantau, C Oliver.   

Abstract

In this study we examined the interaction of opiates with kappa binding sites in the bovine adrenal medulla. [3H]Ethylketocyclazocine (EKC), [3H]etorphine, and [3H]bremazocine stereoselective bindings were used to assay these interactions. The kappa sites were found to be heterogeneous: [3H]bremazocine identified with high affinity all subtypes of these sites. [3H]EKC, in the presence of saturating concentrations of [D-Ala2, D-Leu5]-enkephalin (DADLE) (5 microM), was used to identify kappa 1 sites, on which dynorphin A (1-13) bound with high affinity. Either [3H]EKC or [3H]etorphine in the presence of 5 microM DADLE identified the kappa 2 subtype. This subtype was found to interact with beta-endorphin and especially with the octapeptide Met5-enkephalyl-Arg6-Gly7-Leu8. Furthermore, [3H]etorphine identified in the bovine adrenal medulla a third high-affinity component, in the presence of 5 microM DADLE. This residual interaction was found to be equally stereoselective and presenting kappa selectivity. Met5-enkephalyl-Arg6-Phe7 interacted preferentially with this site. The three kappa subtypes interacted differentially with monovalent (Na+, K+, and Li+) and divalent (Ca2+, Mg2+, and Mn2+) ions by modification of the apparent concentration of the accessible sites and/or by changes of the apparent KD for radioligands. Modifying agents (proteolytic enzymes, thiol-modifying reagents, and A2-phospholipase) produced different effects on each subtype of the kappa site, suggesting a different protein (or protein-lipid?) composition.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2993510     DOI: 10.1111/j.1471-4159.1985.tb04047.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  10 in total

1.  Naloxone potentiates the release of oxytocin induced by systemic administration of cholecystokinin without enhancing the electrical activity of supraoptic oxytocin neurones.

Authors:  G Leng; R E Dyball; S A Way
Journal:  Exp Brain Res       Date:  1992       Impact factor: 1.972

2.  Identification of a novel opioid peptide (Tyr-Val-Pro-Phe-Pro) derived from human alpha S1 casein (alpha S1-casomorphin, and alpha S1-casomorphin amide).

Authors:  M Kampa; S Loukas; A Hatzoglou; P Martin; P M Martin; E Castanas
Journal:  Biochem J       Date:  1996-11-01       Impact factor: 3.857

3.  Chronic exposure of neonatal rat adrenomedullary chromaffin cells to opioids in vitro blunts both hypoxia and hypercapnia chemosensitivity.

Authors:  Shaima Salman; Josef Buttigieg; Min Zhang; Colin A Nurse
Journal:  J Physiol       Date:  2012-11-12       Impact factor: 5.182

4.  Morphine tolerance and inhibition of oxytocin secretion by kappa-opioids acting on the rat neurohypophysis.

Authors:  J A Russell; J E Coombes; G Leng; R J Bicknell
Journal:  J Physiol       Date:  1993-09       Impact factor: 5.182

5.  Functional evidence for multiple receptor activation by kappa-ligands in the inhibition of spinal nociceptive reflexes in the rat.

Authors:  J F Herrero; P M Headley
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

6.  Dihydrocodeinone-hydrazone, dihydrocodeinone-oxime, naloxone-3-OMe-oxime, and clocinnamox fail to irreversibly inhibit opioid kappa receptor binding.

Authors:  Q Ni; H Xu; J S Partilla; B R de Costa; K C Rice; A Borsodi; S Hosztafi; R B Rothman
Journal:  Neurochem Res       Date:  1994-09       Impact factor: 3.996

7.  Effects of opioid peptides and morphine on histamine-induced catecholamine secretion from cultured, bovine adrenal chromaffin cells.

Authors:  B G Livett; P D Marley
Journal:  Br J Pharmacol       Date:  1986-10       Impact factor: 8.739

8.  Characterization and visualization of rat and guinea pig brain kappa opioid receptors: evidence for kappa 1 and kappa 2 opioid receptors.

Authors:  R S Zukin; M Eghbali; D Olive; E M Unterwald; A Tempel
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

9.  Opiate binding differentially associated with oxytocin and vasopressin nerve endings from porcine neurohypophyses.

Authors:  N Falke; R Martin
Journal:  Exp Brain Res       Date:  1988       Impact factor: 1.972

10.  Receptorphin: a conserved peptide derived from the sequence of the opioid receptor, with opioid displacement activity and potent antiproliferative actions in tumor cells.

Authors:  M Kampa; S Loukas; A Tsapis; E Castanas
Journal:  BMC Pharmacol       Date:  2001-11-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.